[go: up one dir, main page]

PE20081375A1 - Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5 - Google Patents

Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5

Info

Publication number
PE20081375A1
PE20081375A1 PE2007001255A PE2007001255A PE20081375A1 PE 20081375 A1 PE20081375 A1 PE 20081375A1 PE 2007001255 A PE2007001255 A PE 2007001255A PE 2007001255 A PE2007001255 A PE 2007001255A PE 20081375 A1 PE20081375 A1 PE 20081375A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
pirrolo
octahydro
antagonists
Prior art date
Application number
PE2007001255A
Other languages
English (en)
Inventor
Remy Lemoine
Chris Richard Melville
David Mark Rotstein
Jutta Wanner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38787632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081375A1 publication Critical patent/PE20081375A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS OCTAHIDRO-PIRROLO[3,4-c]PIRROL DE FORMULA (I), EN DONDE R1 ES FENILO, PIRIDINILO, PIRIMIDILO, OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C6), HALOALQUILO(C1-C6), ENTRE OTROS; UNO DE R2 Y R3 ES H. Y EL OTRO ES A1, A2 O A3; O BIEN JUNTOS CON (CH2)mNR4(CH2)n; DONDE m Y n SON 1 0 2; R4 ES ALQUILO(C1-C6), HALOALQUILO(C1-C6), CH2C=N, -C(=O)R5 O -SO2R5; Ar ES FENILO OPCIONALMENTE SUSTITUIDO CON HALO, ALQUILO(C1-C6), ENTRE OTROS; R7 ES H O ALQUILO (C1-C3). SON SELECCIONADOS: 4-{2-[5-(4,6-DIMETIL-PIRIMIDINA-5-CARBONIL)-HEXAHIDRO-PIRROLO[3,4-c]PIRROL-2-IL]-ETIL}-4-FENIL-PIPERIDINA-1-CARBOXILATO DE TERT-BUTILO, (5-{2-[1-BENZOIL-4-(3-FLUOR-FENIL)-PIPERIDIN-4-IL]-ETIL}-HEXAHIDRO-PIRROLO[3,4-c]PIRROL-2-IL)-(4,6-DIMETIL-PIRIMIDIN-5-IL)-METANONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES CCR5 DE QUIMIOQUINA, SIENDO UTILES EN EL TRATAMIENTO Y PREVENCION DE LA INFECCION DEL VIRUS DE INMUNODEFICIENCIA (VIH)
PE2007001255A 2006-09-18 2007-09-17 Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5 PE20081375A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84533406P 2006-09-18 2006-09-18

Publications (1)

Publication Number Publication Date
PE20081375A1 true PE20081375A1 (es) 2008-10-17

Family

ID=38787632

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001255A PE20081375A1 (es) 2006-09-18 2007-09-17 Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5

Country Status (13)

Country Link
US (1) US7625905B2 (es)
EP (1) EP2066674B1 (es)
JP (1) JP2010503714A (es)
CN (1) CN101516884A (es)
AR (1) AR062798A1 (es)
AT (1) ATE472549T1 (es)
CA (1) CA2662835A1 (es)
CL (1) CL2007002671A1 (es)
DE (1) DE602007007497D1 (es)
ES (1) ES2345130T3 (es)
PE (1) PE20081375A1 (es)
TW (1) TW200821311A (es)
WO (1) WO2008034731A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
EP2720754B1 (en) 2011-06-19 2016-10-19 New York University Leukotoxin e/d as a new anti-inflammatory agent and microbicide
KR20160128345A (ko) 2014-03-26 2016-11-07 에프. 호프만-라 로슈 아게 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서 이환형 화합물
SI3169666T1 (en) 2014-07-15 2018-08-31 Gruenenthal Gmbh SUBSTITUTED DERIVATIVES AZASPIRO (4.5) DECAN
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フェノキシメチル誘導体
EP4091634A1 (en) 2016-03-10 2022-11-23 Janssen Pharmaceutica NV Methods of treating depression using orexin-2 receptor antagonists
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529113A (ja) * 2001-03-07 2004-09-24 ファイザー・プロダクツ・インク ケモカイン受容体活性のモジュレーター
MXPA05006354A (es) * 2002-12-13 2005-08-26 Smithkline Beecham Corp Antagonistas ccr5 como agentes terapeuticos.
DE60322423D1 (de) * 2002-12-13 2008-09-04 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
EP1776362A1 (en) * 2003-07-18 2007-04-25 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
DE602004006424T2 (de) 2003-07-31 2008-05-15 Astrazeneca Ab Piperidinderivate als ccr5-rezeptormodulatoren
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
RU2006146608A (ru) * 2004-06-09 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0403106D0 (sv) 2004-12-20 2004-12-20 Astrazeneca Ab Chemical compounds
EP1987036A1 (en) 2006-02-15 2008-11-05 F.Hoffmann-La Roche Ag Hetero-bycyclic antiviral compounds
EP1987035A1 (en) 2006-02-15 2008-11-05 F.Hoffmann-La Roche Ag Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
CN101516884A (zh) 2009-08-26
EP2066674B1 (en) 2010-06-30
AR062798A1 (es) 2008-12-03
CA2662835A1 (en) 2008-03-27
WO2008034731A1 (en) 2008-03-27
ATE472549T1 (de) 2010-07-15
EP2066674A1 (en) 2009-06-10
CL2007002671A1 (es) 2008-04-18
ES2345130T3 (es) 2010-09-15
DE602007007497D1 (de) 2010-08-12
US7625905B2 (en) 2009-12-01
TW200821311A (en) 2008-05-16
US20080103125A1 (en) 2008-05-01
JP2010503714A (ja) 2010-02-04

Similar Documents

Publication Publication Date Title
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
PE20090183A1 (es) Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5
PE20130158A1 (es) Inhibidores no nucleosidicos de la transcriptasa inversa
PE20120659A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20131377A1 (es) Triazina-oxadiazoles
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20051141A1 (es) Inhibidores de la polimerasa viral
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
PE20090775A1 (es) Nuevos derivados de biarilo
PE20090546A1 (es) Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5
PE20081532A1 (es) Compuestos novedosos
PE20080401A1 (es) DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS
PE20080998A1 (es) Derivados de pirazol como inhibidores del sistema enzimatico cyp450
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20090226A1 (es) PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
PE20080211A1 (es) Compuestos derivados de 6-(bencilo sustituido con heterociclilo)-4-oxoquinolina como inhibidores de integrasa del vih
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20090893A1 (es) Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
PE20091353A1 (es) Nuevos compuestos heterociclicos

Legal Events

Date Code Title Description
FD Application declared void or lapsed